甲状腺乳头状癌转移性淋巴结乙醇消融——临床结局的预测因素
该研究纳入75例在三级转诊中心接受乙醇消融(EA)的甲状腺乳头状癌转移性淋巴结(MLN)患者,评估超声特征、淋巴结手术史、侵袭性组织学亚型或原发肿瘤BRAFV600E突变是否预测EA的长期疗效。中位随访119个月,纯囊性MLN的疗效优于实性和部分囊性MLN(13/13,100% vs 90/121,74%;P=0.039),小MLN(≤0.5 mL)的缓解率高于较大病灶(71/92,77% vs 10/19,53%;P=0.045);BRAFV600E突变、侵袭性亚型或既往淋巴结手术史未显著影响EA疗效。
要点
- 纯囊性转移性淋巴结乙醇消融疗效优于实性和部分囊性淋巴结(13/13,100% vs 90/121,74%;P=0.039)。
- ≤0.5 mL的小淋巴结乙醇消融缓解率高于较大病灶(71/92,77% vs 10/19,53%;P=0.045)。
- BRAFV600E突变、侵袭性组织学亚型或既往淋巴结手术史未显著影响乙醇消融疗效。
核心结论
- 乙醇消融对纯囊性转移性淋巴结高度有效;部分囊性或非囊性且大于0.5 mL的淋巴结反应较差,但许多此类淋巴结仍显示持久缓解。
- BRAFV600E突变、侵袭性组织学亚型或既往无淋巴结手术未对乙醇消融反应产生负面影响。
研究设计与样本
- 研究纳入75例在三级转诊中心接受乙醇消融的甲状腺乳头状癌转移性淋巴结患者。
- 评估最近一次临床指示检查或研究特定检查的治疗反应,并进行原发肿瘤BRAFV600E分析和组织学亚型回顾。
主要发现
- 从初次手术到随访的中位间隔为119个月(范围39-471个月)。
- 纯囊性MLN的结局优于实性和部分囊性MLN(13/13,100% vs 90/121,74%;P=0.039)。
- 小MLN(≤0.5 mL)的缓解率高于较大病灶(71/92,77% vs 10/19,53%;P=0.045)。
- BRAFV600E突变患者与无突变患者的EA反应无差异(80/99,81% vs 17/25,68%;P=0.181)。
- 侵袭性亚型患者与无侵袭性亚型患者的EA反应无差异(22/24,92% vs 75/100,75%;P=0.099)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Ethanol ablation (EA) is a treatment option in recurrent or persistent metastatic lymph nodes (MLNs) from papillary thyroid carcinoma. OBJECTIVE: This work aimed to assess whether ultrasonographic characteristics of the MLN, history of lymph node surgery, aggressive histological subtype, or BRAFV600E mutation in the primary tumor predict long-term response from EA. METHODS: Seventy-five patients who received EA at a tertiary referral center were included. We evaluated treatment response from the most recent clinically indicated examination, or a study-specific examination. BRAFV600E analysis and review of histological subtypes in the primary tumor were conducted. RESULTS: Median interval from initial surgery to follow-up was 119 months (range, 39-471 months). Pure cystic MLN had a better outcome than the solid and partially cystic MLN (13/13, 100% vs 90/121, 74%; P = .039). Small MLNs (≤0.5 mL) had a higher response rate compared to larger lesions (71/92, 77% vs 10/19, 53%; P = .045). We observed no difference in EA response between patients with or without the BRAFV600E mutation (80/99, 81% vs 17/25, 68%; P = .181) or an aggressive subtype (22/24, 92% vs 75/100, 75%; P = .099) in their primary tumors. EA achieved similar rates of locoregional disease control in neck regions with or without previous lymph node surgery (66% vs 63%, P = .825). CONCLUSION: EA was highly effective in pure cystic MLNs. Partially cystic or noncystic MLNs over 0.5 mL were less responsive, though many of these MLNs still showed a lasting response. BRAFV600E mutation, aggressive histological subtype, or absence of prior lymph node surgery did not negatively affect EA response.
引用
- Frich PS, Sigstad E, Berstad AE, et al. Ethanol Ablation of Metastatic Lymph Nodes in Patients With Papillary Thyroid Carcinoma-Predictors of Clinical Outcome. J Clin Endocrinol Metab. 2025. PMID: 40405530. doi:10.1210/clinem/dgaf298
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。